Should You Follow Carl Icahn Into Bausch Health Companies (TSX:BHC)?

Bausch Health Companies (TSX:BHC)(NYSE:BHC) is surging thanks to activist investor Carl Icahn, who recently took a big stake in the company.

| More on:

Bausch Health Companies (TSX:BHC)(NYSE:BHC) has been picking up traction in recent weeks thanks in part to a huge vote of confidence by billionaire hedge fund manager Carl Icahn, who took a huge stake in the company in the fourth quarter of 2020.

The Canadian pharmaceutical play, formerly known as the infamous Valeant Pharmaceuticals, has since moved on from the days of Michael Pearson and the M&A spree. With an incredible manager in Joe Papa at the helm and a plethora of incredible eye care, dermatology, and gastrointestinal (GI) assets, the firm is undoubtedly one of very few shining healthcare stocks on the TSX Index.

Shares of Bausch Health are now up over 111% from their March lows, with most recent gains coming since November 2020. I’ve been urging investors to back up the truck on Bausch Health stock on the dip ahead of the spin-off of its Bausch + Lomb business. While the stock is within 3% of hitting its pre-pandemic levels, I’d still argue that there’s ample value to be had and would encourage investors to think strongly about initiating a position while shares are trading at $39 and change.

Carl Icahn takes a big stake in Bausch Health

The legendary activist investor Carl Icahn reportedly took a 7.83% stake (27.8 million shares) in Bausch Health Companies, and you can bet he’s going to be active with his position in an effort to enhance shareholder value in the underrated and still tremendously undervalued Canadian pharma play.

Big changes are coming to Bausch Health. Given Carl Icahn’s extensive track record of success with activist investments, I think it would be a wise idea to ride on the man’s coattails before he has a chance to do work his magic.

The Bausch story hasn’t looked this good in a while

Joe Papa has done an unbelievable job of meeting (and exceeding) deleveraging targets, chipping away at the mountain of debt accumulated back in the days of Valeant’s debt-fueled acquisition spree. More recently, Bausch is slated to cut another US$100 million worth of debt from cash flow from operations.

“As Bausch Health continues its recovery from the effects of the COVID-19 pandemic, we also remain focused on repaying our debt by generating cash through strong business execution and efficient management of our operations.” Bausch Health CEO Joe Papa said.

Undoubtedly, there remain a plethora of challenges ahead. Still, there’s no denying that Papa has continued to do a remarkable job of turning the ship around, despite the numerous curve balls thrown his way.

Moving ahead, I think Icahn’s involvement in the company only serves to enhance the Bausch investment thesis. The company already has an exceptional steward in Joe Papa. With Icahn on board, I think Bausch could really take it to the next level.

Foolish takeaway

While I’m not an advocate of chasing stocks that have recently surged by double-digit percentage points, I am willing to make an exception with Bausch. The stock remains cheap at just 1.4 times its book value. That’s a low price to pay for a firm that owns incredible assets and the stewardship to take it to the next level. I’m a huge believer in both Papa and Icahn and would consider initiating a position in the name on a pullback.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joey Frenette has no position in any of the stocks mentioned. Tom Gardner owns shares of Bausch Health Companies. The Motley Fool owns shares of and recommends Bausch Health Companies.

More on Stocks for Beginners

a person watches a downward arrow crash through the floor
Dividend Stocks

3 Everyday CRA Red Flags Investors Should Really Know

The CRA can be a blessing and a curse, but if you make sure to follow the rules and not…

Read more »

Train cars pass over trestle bridge in the mountains
Dividend Stocks

Canadian National Railway Stock is on Sale: Why Now is the Time to Invest

CNR stock has long been a top stock, with a solid position in a railway duopoly. But right now is…

Read more »

ETF stands for Exchange Traded Fund
Dividend Stocks

This 7.9% Dividend Stock Pays Cash Every Month

We all want dividends, and having them come out monthly is ideal! But this might be a strong choice for…

Read more »

data analyze research
Stocks for Beginners

The Best TSX Stocks for Canadians to Buy With $700 on Hand

These TSX stocks may not cost much but can provide you with stability as well as growth like no other…

Read more »

Dividend Stocks

Top Canadian Stocks to Buy Now and Hold for a Lifetime in a TFSA

If you want stability in your long-term TFSA, then these four are choices you can pick up again and again.

Read more »

Senior uses a laptop computer
Dividend Stocks

7.4% Dividend Yield? Yes Please! I’ll Buy This Dividend Stock for Decades

This top dividend stock not only has a top dividend yield, it's offering decades of income for investors right now!

Read more »

dividend growth for passive income
Top TSX Stocks

1 Magnificent Canadian Stock Down 9 Percent to Buy and Hold Forever

There are some really great stocks on the market for any portfolio, but this one magnificent Canadian stock screams buy.

Read more »

Man holds Canadian dollars in differing amounts
Dividend Stocks

This Dividend Stock is Set to Beat the TSX Again and Again

When it comes to easy wins, goeasy stock is one of the easiest with growth under its belt, and even…

Read more »